Lazard Initiated Coverage on Vanda Pharma with a Buy Rating, $11 Price Target, Neurocrine Biosciences with a Buy and $13 PT, Repros Therapeutics with Buy, $26 PT
Get News First. Profit Faster
With Benzinga Professional get unlimited access to ALL content! PLUS:
- REALTIME NEWSFEED
- REALTIME AUDIO NEWS
- FULL CALENDAR SUITE
- CHAT WITH OUR NEWS DESK
RECENT PRO ALERTS
Credit Suisse Maintains Outperform on Thermo Fisher Scientific Inc, Raises PT to $89.00
08:18am - April 16, 2013Credit Suisse Downgrades Life Technologies Corporation to Neutral, Raises PT to $76.00
08:18am - April 16, 2013Credit Suisse Initiates Coverage on Five Oaks Investment at Outperform, Announces $16.00 PT
08:17am - April 16, 2013
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted in: Price Target, Initiation, Analyst Ratings